Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Historisch | Analysen |
02.07.2025 18:08:14
|
EQS-News: Biotest AG: Annual General Meeting approves dividend distribution
EQS-News: Biotest AG
/ Key word(s): AGM/EGM
PRESS RELEASE Biotest AG: Annual General Meeting approves dividend distribution
The shareholders approved the actions of the members of the Executive Board and Supervisory Board for the 2024 financial year by a large majority. All resolutions on the other items on the agenda submitted for resolution were also passed by a large majority in accordance with the management's proposals. The Annual General Meeting speech by Dr. Jörg Schüttrumpf, CEO of Biotest AG, is available at Annual General Meeting 2025 Shareholders' Meeting 2025. About Biotest Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,600 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain (www.grifols.com). IR contact Dr Monika Baumann (Buttkereit) Phone: +49-6103-801-4406
PR contact Miriam Oehme Phone: +49 -152 07016992 Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201 Preference shares: securities’ ID No. 522723; ISIN DE0005227235 Listing: Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate Disclaimer
02.07.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
Language: | English |
Company: | Biotest AG |
Landsteinerstraße 5 | |
63303 Dreieich | |
Germany | |
Phone: | 0 61 03 - 8 01-0 |
E-mail: | ir@biotest.com |
Internet: | www.biotest.com |
ISIN: | DE0005227235, DE0005227201 |
WKN: | 522723, 522720 |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 2164354 |
End of News | EQS News Service |
|
2164354 02.07.2025 CET/CEST
Nachrichten zu Biotest AG Vz.
Im BX Morningcall werden folgende Aktien analysiert und erklärt – heute mit dem monatlichen Rebalancing:
NEU✅ Broadcom Inc
NEU✅ Quanta Services
NEU✅ JPMorgan Chase & Co
inklusive Rebalancing:
❌ Wolters Kluwer
❌ Thales
❌ Waste Connections
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Raiffeisen am 02.07.2025
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Zölle und US-Arbeitsmarktdaten im Fokus: SMI über 12'000 Punkten -- DAX in Grün -- Asiens Börsen uneins - Hongkong schwachDer heimische Aktienmarkt präsentiert sich am Donnerstag freundlich. Der deutsche Leitindex zeigt sich stärker. In Fernost finden die Börsen am Donnerstag keine einheitliche Richtung.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |